Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas is a leader in the emerging field of protein degradation, using its proprietary technology platform to develop novel therapeutics for oncology and neurology-related diseases. The company's PROteolysis TArgeting Chimera (PROTAC) technology allows for the targeted removal of disease-causing proteins by using the body's natural protein disposal system. With a strong pipeline of product candidates in various stages of development and positive clinical data, Arvinas has the potential for significant growth in the future. While there are standard risks associated with the biotechnology industry, the company's approach and progress thus far make it a promising investment opportunity.

Bears say

Arvinas is a clinical-stage biotechnology company with a promising protein degradation platform, but their current pipeline of therapeutics is still in early clinical stages and may not see full commercialization until 2029. Additionally, peak penetration of their upcoming drug, ARV-393, is only projected to reach 30%, and the company's revenue may be limited due to an 18% royalty sharing agreement for ex-US commercialization. Overall, while Arvinas shows potential, their current financials do not support a positive outlook at this time.

Arvinas Inc (ARVN) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 16 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.